Literature DB >> 1436703

Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease.

S J Pearson1, G P Reynolds.   

Abstract

Concentrations of the neurotoxic tryptophan metabolite, 3-hydroxykynurenine, were determined in brain tissue taken post-mortem from patients with Huntington's disease and Alzheimer's disease. 3-Hydroxykynurenine was substantially and significantly increased in all three brain areas studied in Huntington's disease, but not significantly increased in the cortex in Alzheimer's disease, when compared to matched controls. These results demonstrate a possible dysfunction of tryptophan metabolism, via the kynurenine pathway, in Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1436703     DOI: 10.1016/0304-3940(92)90749-w

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  45 in total

1.  Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Laura Amori; Paolo Guidetti; Paul J Muchowski; Robert Schwarcz
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

2.  Kynurenine inhibits fibroblast growth factor 2-mediated expression of crystallins and MIP26 in lens epithelial cells.

Authors:  Maneesh Mailankot; Scott Howell; Ram H Nagaraj
Journal:  Biochim Biophys Acta       Date:  2010-05-15

3.  Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine.

Authors:  S Okuda; N Nishiyama; H Saito; H Katsuki
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

4.  An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease.

Authors:  S J Pearson; A Meldrum; G P Reynolds
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 5.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

6.  Neocortical neurotransmitter markers in Huntington's disease.

Authors:  S J Pearson; G P Reynolds
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 7.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

Review 8.  Tryptophan, adenosine, neurodegeneration and neuroprotection.

Authors:  T W Stone; C M Forrest; G M Mackay; N Stoy; L G Darlington
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

Review 9.  Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies.

Authors:  D Zádori; P Klivényi; E Vámos; F Fülöp; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2009-07-18       Impact factor: 3.575

Review 10.  Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.

Authors:  Robert Schwarcz; Paolo Guidetti; Korrapati V Sathyasaikumar; Paul J Muchowski
Journal:  Prog Neurobiol       Date:  2009-04-24       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.